Osaka, Japan and Somerville, MA, April 5 2017 – Finch Therapeutics, a privately held microbiome engineering company, and Takeda Pharmaceutical Company Limited (“Takeda”) (TSE: 4502), today announced a global collaboration agreement to jointly develop FIN-524. […]
Saint-Prex, Switzerland & Roseville, MN, US – 05 April, 2018 — Ferring Pharmaceuticals* and Rebiotix Inc. today announce that they have agreed to the acquisition of Rebiotix by Ferring. This acquisition brings together two innovative […]
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in Life science microbiome investment, today announces that it has launched AVF, the innovative venture capital fund, targeted at supporting companies in the […]
Today, Bayer and Ginkgo Bioworks announced the official name of its joint venture, Joyn Bio. Bayer and Ginkgo founded Joyn Bio in September 2017 and have since established research operations in Boston, Massachusetts and opened […]
MyBiotics Pharma Ltd., a microbiome therapeutics company, announced today that it has entered into a second option agreement with Ferring Holding Ltd. for the validation of MyBiotics’ microbiome-based therapeutics in the field of women’s health. […]
Boost Biomes today announced the close of a $2.05Mseed round — led by Nimble Ventures and Viking Global Investors and including other participants such as Tencent — to develop microbiome-based products. Boost Biomes’ proprietary DNA […]
Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today provided a clinical programs update and reported financial results for […]